✨ Free AI Report
Intra-Cellular Therapies, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Intra-Cellular Therapies, Inc.
Company Research

Intra-Cellular Therapies, Inc.: Business Overview, Financials & Competitive Analysis

Intra-Cellular Therapies, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). ITCI was a high-value biopharmaceutical innovator with blockbuster potential in CNS disorders, successfully acquired by J&J to strengthen its neuropsychiatric portfolio. ITCI delivered exceptional commercial success with its flagship product CAPLYTA, achieving significant FDA approvals and projected peak sales exceeding $5 billion. The company's acquisition by Johnson & Johnson.

What is Intra-Cellular Therapies, Inc.'s industry? Intra-Cellular Therapies, Inc. (intracellulartherapies.com) operates in Neurology Drugs. AskCyborg classifies Intra-Cellular Therapies, Inc. under Neurology Drugs in its company registry.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervou...

8/ 10Strong

Cyborg Score thesis

ITCI was a high-value biopharmaceutical innovator with blockbuster potential in CNS disorders, successfully acquired by J&J to...

Read the full analyst-debate transcript →
Industry Neurology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Intra-Cellular Therapies, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Intra-Cellular Therapies, Inc.

AskCyborg analysts argue the bull and bear cases for Intra-Cellular Therapies, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Intra-Cellular Therapies, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Intra-Cellular Therapies, Inc. Overview

Pro stress-test →

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. In early 2025, Johnson & Johnson announced the completion of its acquisition of Intra-Cellular Therapies for approximately $15 billion, with J&J acquiring all outstanding shares for $132.00 per share in cash.

Strategic Profile

Pro stress-test →

The company's product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder. CAPLYTA is noted for its unique mechanism of action that modulates dopamine, serotonin, and glutamate levels simultaneously, with analysts projecting that peak sales could exceed $5 billion annually.

Competitive Landscape

Pro stress-test →

The success of Intra-Cellular Therapies highlighted a shift in the neuropsychiatry market, as unlike traditional medications with heavy side-effect profiles, ITCI's approach to intracellular signaling aimed for higher efficacy with fewer metabolic complications. Main competitors in the antipsychotic and bipolar depression space include Janssen (part of J&J parent company), Otsuka/Lundbeck, and Allergan in the neuropsychiatric therapeutics segment.

Industry Context

Intra-Cellular Therapies, Inc. operates in Neurology Drugs.

Key facts

Founded: 2002 · Headquarters: New York, US · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Intra-Cellular Therapies, Inc..

  • CAPLYTA achieved FDA approvals for both schizophrenia and bipolar depression, representing a broad commercial opportunity in CNS markets
  • Acquisition by Johnson & Johnson (early 2025) at $132/share provides validation of the company's technology and market positioning
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Early 2025Johnson & Johnson completed acquisition of Intra-Cellular Therapies for approximately $15 billion
  • Phase IIILumateperone in Phase III clinical trials for bipolar depression and autism spectrum disorder treatment
  • +1 moreTrack every material event for Intra-Cellular Therapies, Inc. as it happens. Explore monitoring →
Get alerted when Intra-Cellular Therapies, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Antipsychotics/Bipolar TreatmentsLeading antipsychotic and neuropsychiatric treatments→CNS TherapeuticsCompeting neuropsychiatric and CNS drug developer→Neuropsychiatric TherapeuticsAlternative CNS disorder treatment solutions→

Compare Intra-Cellular Therapies, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Intra-Cellular Therapies, Inc. operates in Neurology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Neurology Drugs research →
NEW · MCP server

Ask your AI assistant about Intra-Cellular Therapies, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Intra-Cellular Therapies, Inc. and its top competitor on Cyborg Score”
“What did Intra-Cellular Therapies, Inc. do this quarter?”
“Is Intra-Cellular Therapies, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Intra-Cellular Therapies, Inc. do?+
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervou...
What is Intra-Cellular Therapies, Inc.'s Cyborg Score?+
Intra-Cellular Therapies, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Intra-Cellular Therapies, Inc.'s main competitors?+
Named competitors include Antipsychotics/Bipolar Treatments, CNS Therapeutics, Neuropsychiatric Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Intra-Cellular Therapies, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Intra-Cellular Therapies, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Intra-Cellular Therapies, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.